Review



human dlbcl cancer cell lines  (Ubigene Biosciences Co Ltd)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Ubigene Biosciences Co Ltd human dlbcl cancer cell lines
    Nrf2 is differentially distributed in different cancer stages and subtypes of <t>DLBCL.</t> (A) Elevated NFE2L2 (Nrf2) mRNA levels in DLBCL tissues compared with in normal tissues. (B) Increased % Nrf2-positive cancer cells in advanced stages of DLBCL. (C) Higher frequency of Nrf2-positive cancer cells in the GCB subtype of DLBCL compared with that in the ABC subtype. (D) Higher Nrf2-positive cancer cell numbers in the GCB subtype across all stages of DLBCL. *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001. All IHC sample images are ×20 magnification. ns, no significance; DLBCL, diffuse large B-cell lymphoma; Nrf2, nuclear factor erythroid 2-related factor 2; ABC, activated B-cell; GCB, germinal center B-cell; TPM, transcripts per million; IHC, immunohistochemistry.
    Human Dlbcl Cancer Cell Lines, supplied by Ubigene Biosciences Co Ltd, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human dlbcl cancer cell lines/product/Ubigene Biosciences Co Ltd
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    human dlbcl cancer cell lines - by Bioz Stars, 2025-01
    86/100 stars

    Images

    1) Product Images from "Biomarker potential of nuclear Nrf2 activation in the ABC subtype of diffuse large B‑cell lymphoma"

    Article Title: Biomarker potential of nuclear Nrf2 activation in the ABC subtype of diffuse large B‑cell lymphoma

    Journal: Oncology Letters

    doi: 10.3892/ol.2024.14776

    Nrf2 is differentially distributed in different cancer stages and subtypes of DLBCL. (A) Elevated NFE2L2 (Nrf2) mRNA levels in DLBCL tissues compared with in normal tissues. (B) Increased % Nrf2-positive cancer cells in advanced stages of DLBCL. (C) Higher frequency of Nrf2-positive cancer cells in the GCB subtype of DLBCL compared with that in the ABC subtype. (D) Higher Nrf2-positive cancer cell numbers in the GCB subtype across all stages of DLBCL. *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001. All IHC sample images are ×20 magnification. ns, no significance; DLBCL, diffuse large B-cell lymphoma; Nrf2, nuclear factor erythroid 2-related factor 2; ABC, activated B-cell; GCB, germinal center B-cell; TPM, transcripts per million; IHC, immunohistochemistry.
    Figure Legend Snippet: Nrf2 is differentially distributed in different cancer stages and subtypes of DLBCL. (A) Elevated NFE2L2 (Nrf2) mRNA levels in DLBCL tissues compared with in normal tissues. (B) Increased % Nrf2-positive cancer cells in advanced stages of DLBCL. (C) Higher frequency of Nrf2-positive cancer cells in the GCB subtype of DLBCL compared with that in the ABC subtype. (D) Higher Nrf2-positive cancer cell numbers in the GCB subtype across all stages of DLBCL. *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001. All IHC sample images are ×20 magnification. ns, no significance; DLBCL, diffuse large B-cell lymphoma; Nrf2, nuclear factor erythroid 2-related factor 2; ABC, activated B-cell; GCB, germinal center B-cell; TPM, transcripts per million; IHC, immunohistochemistry.

    Techniques Used: Immunohistochemistry

    Immunohistochemical staining of Nrf2 localization in DLBCL. (A) Active Nrf2 is distributed in both the nucleus and cytoplasm, covering the entire cell (black arrows). (B) Nrf2 localized in the cytoplasm surrounds the nucleus (red arrows indicate cytoplasmic Nrf2; nucleus stained with hematoxylin). (C) Nuclear Nrf2 is predominantly observed in the ABC subtype of DLBCL and is absent in the GCB subtype. All IHC sample images are ×40 magnification. DLBCL, diffuse large B-cell lymphoma; Nrf2, nuclear factor erythroid 2-related factor 2; ABC, activated B-cell; GCB, germinal center B-cell.
    Figure Legend Snippet: Immunohistochemical staining of Nrf2 localization in DLBCL. (A) Active Nrf2 is distributed in both the nucleus and cytoplasm, covering the entire cell (black arrows). (B) Nrf2 localized in the cytoplasm surrounds the nucleus (red arrows indicate cytoplasmic Nrf2; nucleus stained with hematoxylin). (C) Nuclear Nrf2 is predominantly observed in the ABC subtype of DLBCL and is absent in the GCB subtype. All IHC sample images are ×40 magnification. DLBCL, diffuse large B-cell lymphoma; Nrf2, nuclear factor erythroid 2-related factor 2; ABC, activated B-cell; GCB, germinal center B-cell.

    Techniques Used: Immunohistochemical staining, Staining

    Keap1 expression in DLBCL, especially in the advanced staged and ABC subtype. (A) KEAP1 mRNA is significantly upregulated in DLBCL compared with that in the controls in The Cancer Genome Atlas and Genotype-Tissue Expression databases. (B) Significantly higher Keap1 expression in the advanced stages of DLBCL than in the early stages. (C) Significantly higher Keap1 expression in patients with DLBCL of the ABC subtype than the GCB subtype. (D) KEAP1 mRNA expression in DLBCL cell lines (HT and U2932). *P<0.05; **P<0.01. All IHC sample images are ×20 magnification. DLBCL, diffuse large B-cell lymphoma; Keap1, kelch-like ECH-associated protein 1; ABC, activated B-cell; GCB, germinal center B-cell; TPM, transcripts per million; IHC, immunohistochemistry.
    Figure Legend Snippet: Keap1 expression in DLBCL, especially in the advanced staged and ABC subtype. (A) KEAP1 mRNA is significantly upregulated in DLBCL compared with that in the controls in The Cancer Genome Atlas and Genotype-Tissue Expression databases. (B) Significantly higher Keap1 expression in the advanced stages of DLBCL than in the early stages. (C) Significantly higher Keap1 expression in patients with DLBCL of the ABC subtype than the GCB subtype. (D) KEAP1 mRNA expression in DLBCL cell lines (HT and U2932). *P<0.05; **P<0.01. All IHC sample images are ×20 magnification. DLBCL, diffuse large B-cell lymphoma; Keap1, kelch-like ECH-associated protein 1; ABC, activated B-cell; GCB, germinal center B-cell; TPM, transcripts per million; IHC, immunohistochemistry.

    Techniques Used: Expressing, Immunohistochemistry

    Increased LC3B (encoded by MAP1LC3B) expression in DLBCL. (A) Elevated MAP1LC3B mRNA expression in DLBCL compared with controls in The Cancer Genome Atlas and Genotype-Tissue Expression databases. (B) LC3B expression across the early and advanced stages of DLBCL. (C) LC3B expression in the DLBCL GCB and ABC subtypes. All IHC sample images are ×20 magnification. ns, no significance; DLBCL, diffuse large B-cell lymphoma; TPM, transcripts per million; IHC, immunohistochemistry; MAP1LC3B, microtubule-associated protein 1 light chain 3β.
    Figure Legend Snippet: Increased LC3B (encoded by MAP1LC3B) expression in DLBCL. (A) Elevated MAP1LC3B mRNA expression in DLBCL compared with controls in The Cancer Genome Atlas and Genotype-Tissue Expression databases. (B) LC3B expression across the early and advanced stages of DLBCL. (C) LC3B expression in the DLBCL GCB and ABC subtypes. All IHC sample images are ×20 magnification. ns, no significance; DLBCL, diffuse large B-cell lymphoma; TPM, transcripts per million; IHC, immunohistochemistry; MAP1LC3B, microtubule-associated protein 1 light chain 3β.

    Techniques Used: Expressing, Immunohistochemistry

    Nitrotyrosine expression in different DLBCL stages and subgroups. (A) Nitrotyrosine-positive cells were more prevalent in the advanced stages of DLBCL. (B) Higher frequency of nitrotyrosine-positive cells was observed in the ABC subtype of DLBCL. All IHC sample images are ×20 magnification. ns, no significance; DLBCL, diffuse large B-cell lymphoma; IHC, immunohistochemistry.
    Figure Legend Snippet: Nitrotyrosine expression in different DLBCL stages and subgroups. (A) Nitrotyrosine-positive cells were more prevalent in the advanced stages of DLBCL. (B) Higher frequency of nitrotyrosine-positive cells was observed in the ABC subtype of DLBCL. All IHC sample images are ×20 magnification. ns, no significance; DLBCL, diffuse large B-cell lymphoma; IHC, immunohistochemistry.

    Techniques Used: Expressing, Immunohistochemistry



    Similar Products

    human dlbcl cancer cell lines  (Ubigene Biosciences Co Ltd)
    86
    Ubigene Biosciences Co Ltd human dlbcl cancer cell lines
    Nrf2 is differentially distributed in different cancer stages and subtypes of <t>DLBCL.</t> (A) Elevated NFE2L2 (Nrf2) mRNA levels in DLBCL tissues compared with in normal tissues. (B) Increased % Nrf2-positive cancer cells in advanced stages of DLBCL. (C) Higher frequency of Nrf2-positive cancer cells in the GCB subtype of DLBCL compared with that in the ABC subtype. (D) Higher Nrf2-positive cancer cell numbers in the GCB subtype across all stages of DLBCL. *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001. All IHC sample images are ×20 magnification. ns, no significance; DLBCL, diffuse large B-cell lymphoma; Nrf2, nuclear factor erythroid 2-related factor 2; ABC, activated B-cell; GCB, germinal center B-cell; TPM, transcripts per million; IHC, immunohistochemistry.
    Human Dlbcl Cancer Cell Lines, supplied by Ubigene Biosciences Co Ltd, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human dlbcl cancer cell lines/product/Ubigene Biosciences Co Ltd
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    human dlbcl cancer cell lines - by Bioz Stars, 2025-01
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    Nrf2 is differentially distributed in different cancer stages and subtypes of DLBCL. (A) Elevated NFE2L2 (Nrf2) mRNA levels in DLBCL tissues compared with in normal tissues. (B) Increased % Nrf2-positive cancer cells in advanced stages of DLBCL. (C) Higher frequency of Nrf2-positive cancer cells in the GCB subtype of DLBCL compared with that in the ABC subtype. (D) Higher Nrf2-positive cancer cell numbers in the GCB subtype across all stages of DLBCL. *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001. All IHC sample images are ×20 magnification. ns, no significance; DLBCL, diffuse large B-cell lymphoma; Nrf2, nuclear factor erythroid 2-related factor 2; ABC, activated B-cell; GCB, germinal center B-cell; TPM, transcripts per million; IHC, immunohistochemistry.

    Journal: Oncology Letters

    Article Title: Biomarker potential of nuclear Nrf2 activation in the ABC subtype of diffuse large B‑cell lymphoma

    doi: 10.3892/ol.2024.14776

    Figure Lengend Snippet: Nrf2 is differentially distributed in different cancer stages and subtypes of DLBCL. (A) Elevated NFE2L2 (Nrf2) mRNA levels in DLBCL tissues compared with in normal tissues. (B) Increased % Nrf2-positive cancer cells in advanced stages of DLBCL. (C) Higher frequency of Nrf2-positive cancer cells in the GCB subtype of DLBCL compared with that in the ABC subtype. (D) Higher Nrf2-positive cancer cell numbers in the GCB subtype across all stages of DLBCL. *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001. All IHC sample images are ×20 magnification. ns, no significance; DLBCL, diffuse large B-cell lymphoma; Nrf2, nuclear factor erythroid 2-related factor 2; ABC, activated B-cell; GCB, germinal center B-cell; TPM, transcripts per million; IHC, immunohistochemistry.

    Article Snippet: Human DLBCL cancer cell lines, U2932 (Guangzhou Ubigene Biosciences Co., Ltd.) and HT (cat. no. 60486; Bioresource Collection and Research Center, Taiwan) were cultured in RPMI-1640 supplemented with 10% FBS (Merck KGaA), 2 mM L-glutamine (Gibco; Thermo Fisher Scientific, Inc.), 10 mM HEPES (BioConcept AG), 1 mM sodium pyruvate (Gibco; Thermo Fisher Scientific, Inc.) and 1% penicillin/streptomycin (Gibco; Thermo Fisher Scientific, Inc.) in 5% CO 2 at 37°C.

    Techniques: Immunohistochemistry

    Immunohistochemical staining of Nrf2 localization in DLBCL. (A) Active Nrf2 is distributed in both the nucleus and cytoplasm, covering the entire cell (black arrows). (B) Nrf2 localized in the cytoplasm surrounds the nucleus (red arrows indicate cytoplasmic Nrf2; nucleus stained with hematoxylin). (C) Nuclear Nrf2 is predominantly observed in the ABC subtype of DLBCL and is absent in the GCB subtype. All IHC sample images are ×40 magnification. DLBCL, diffuse large B-cell lymphoma; Nrf2, nuclear factor erythroid 2-related factor 2; ABC, activated B-cell; GCB, germinal center B-cell.

    Journal: Oncology Letters

    Article Title: Biomarker potential of nuclear Nrf2 activation in the ABC subtype of diffuse large B‑cell lymphoma

    doi: 10.3892/ol.2024.14776

    Figure Lengend Snippet: Immunohistochemical staining of Nrf2 localization in DLBCL. (A) Active Nrf2 is distributed in both the nucleus and cytoplasm, covering the entire cell (black arrows). (B) Nrf2 localized in the cytoplasm surrounds the nucleus (red arrows indicate cytoplasmic Nrf2; nucleus stained with hematoxylin). (C) Nuclear Nrf2 is predominantly observed in the ABC subtype of DLBCL and is absent in the GCB subtype. All IHC sample images are ×40 magnification. DLBCL, diffuse large B-cell lymphoma; Nrf2, nuclear factor erythroid 2-related factor 2; ABC, activated B-cell; GCB, germinal center B-cell.

    Article Snippet: Human DLBCL cancer cell lines, U2932 (Guangzhou Ubigene Biosciences Co., Ltd.) and HT (cat. no. 60486; Bioresource Collection and Research Center, Taiwan) were cultured in RPMI-1640 supplemented with 10% FBS (Merck KGaA), 2 mM L-glutamine (Gibco; Thermo Fisher Scientific, Inc.), 10 mM HEPES (BioConcept AG), 1 mM sodium pyruvate (Gibco; Thermo Fisher Scientific, Inc.) and 1% penicillin/streptomycin (Gibco; Thermo Fisher Scientific, Inc.) in 5% CO 2 at 37°C.

    Techniques: Immunohistochemical staining, Staining

    Keap1 expression in DLBCL, especially in the advanced staged and ABC subtype. (A) KEAP1 mRNA is significantly upregulated in DLBCL compared with that in the controls in The Cancer Genome Atlas and Genotype-Tissue Expression databases. (B) Significantly higher Keap1 expression in the advanced stages of DLBCL than in the early stages. (C) Significantly higher Keap1 expression in patients with DLBCL of the ABC subtype than the GCB subtype. (D) KEAP1 mRNA expression in DLBCL cell lines (HT and U2932). *P<0.05; **P<0.01. All IHC sample images are ×20 magnification. DLBCL, diffuse large B-cell lymphoma; Keap1, kelch-like ECH-associated protein 1; ABC, activated B-cell; GCB, germinal center B-cell; TPM, transcripts per million; IHC, immunohistochemistry.

    Journal: Oncology Letters

    Article Title: Biomarker potential of nuclear Nrf2 activation in the ABC subtype of diffuse large B‑cell lymphoma

    doi: 10.3892/ol.2024.14776

    Figure Lengend Snippet: Keap1 expression in DLBCL, especially in the advanced staged and ABC subtype. (A) KEAP1 mRNA is significantly upregulated in DLBCL compared with that in the controls in The Cancer Genome Atlas and Genotype-Tissue Expression databases. (B) Significantly higher Keap1 expression in the advanced stages of DLBCL than in the early stages. (C) Significantly higher Keap1 expression in patients with DLBCL of the ABC subtype than the GCB subtype. (D) KEAP1 mRNA expression in DLBCL cell lines (HT and U2932). *P<0.05; **P<0.01. All IHC sample images are ×20 magnification. DLBCL, diffuse large B-cell lymphoma; Keap1, kelch-like ECH-associated protein 1; ABC, activated B-cell; GCB, germinal center B-cell; TPM, transcripts per million; IHC, immunohistochemistry.

    Article Snippet: Human DLBCL cancer cell lines, U2932 (Guangzhou Ubigene Biosciences Co., Ltd.) and HT (cat. no. 60486; Bioresource Collection and Research Center, Taiwan) were cultured in RPMI-1640 supplemented with 10% FBS (Merck KGaA), 2 mM L-glutamine (Gibco; Thermo Fisher Scientific, Inc.), 10 mM HEPES (BioConcept AG), 1 mM sodium pyruvate (Gibco; Thermo Fisher Scientific, Inc.) and 1% penicillin/streptomycin (Gibco; Thermo Fisher Scientific, Inc.) in 5% CO 2 at 37°C.

    Techniques: Expressing, Immunohistochemistry

    Increased LC3B (encoded by MAP1LC3B) expression in DLBCL. (A) Elevated MAP1LC3B mRNA expression in DLBCL compared with controls in The Cancer Genome Atlas and Genotype-Tissue Expression databases. (B) LC3B expression across the early and advanced stages of DLBCL. (C) LC3B expression in the DLBCL GCB and ABC subtypes. All IHC sample images are ×20 magnification. ns, no significance; DLBCL, diffuse large B-cell lymphoma; TPM, transcripts per million; IHC, immunohistochemistry; MAP1LC3B, microtubule-associated protein 1 light chain 3β.

    Journal: Oncology Letters

    Article Title: Biomarker potential of nuclear Nrf2 activation in the ABC subtype of diffuse large B‑cell lymphoma

    doi: 10.3892/ol.2024.14776

    Figure Lengend Snippet: Increased LC3B (encoded by MAP1LC3B) expression in DLBCL. (A) Elevated MAP1LC3B mRNA expression in DLBCL compared with controls in The Cancer Genome Atlas and Genotype-Tissue Expression databases. (B) LC3B expression across the early and advanced stages of DLBCL. (C) LC3B expression in the DLBCL GCB and ABC subtypes. All IHC sample images are ×20 magnification. ns, no significance; DLBCL, diffuse large B-cell lymphoma; TPM, transcripts per million; IHC, immunohistochemistry; MAP1LC3B, microtubule-associated protein 1 light chain 3β.

    Article Snippet: Human DLBCL cancer cell lines, U2932 (Guangzhou Ubigene Biosciences Co., Ltd.) and HT (cat. no. 60486; Bioresource Collection and Research Center, Taiwan) were cultured in RPMI-1640 supplemented with 10% FBS (Merck KGaA), 2 mM L-glutamine (Gibco; Thermo Fisher Scientific, Inc.), 10 mM HEPES (BioConcept AG), 1 mM sodium pyruvate (Gibco; Thermo Fisher Scientific, Inc.) and 1% penicillin/streptomycin (Gibco; Thermo Fisher Scientific, Inc.) in 5% CO 2 at 37°C.

    Techniques: Expressing, Immunohistochemistry

    Nitrotyrosine expression in different DLBCL stages and subgroups. (A) Nitrotyrosine-positive cells were more prevalent in the advanced stages of DLBCL. (B) Higher frequency of nitrotyrosine-positive cells was observed in the ABC subtype of DLBCL. All IHC sample images are ×20 magnification. ns, no significance; DLBCL, diffuse large B-cell lymphoma; IHC, immunohistochemistry.

    Journal: Oncology Letters

    Article Title: Biomarker potential of nuclear Nrf2 activation in the ABC subtype of diffuse large B‑cell lymphoma

    doi: 10.3892/ol.2024.14776

    Figure Lengend Snippet: Nitrotyrosine expression in different DLBCL stages and subgroups. (A) Nitrotyrosine-positive cells were more prevalent in the advanced stages of DLBCL. (B) Higher frequency of nitrotyrosine-positive cells was observed in the ABC subtype of DLBCL. All IHC sample images are ×20 magnification. ns, no significance; DLBCL, diffuse large B-cell lymphoma; IHC, immunohistochemistry.

    Article Snippet: Human DLBCL cancer cell lines, U2932 (Guangzhou Ubigene Biosciences Co., Ltd.) and HT (cat. no. 60486; Bioresource Collection and Research Center, Taiwan) were cultured in RPMI-1640 supplemented with 10% FBS (Merck KGaA), 2 mM L-glutamine (Gibco; Thermo Fisher Scientific, Inc.), 10 mM HEPES (BioConcept AG), 1 mM sodium pyruvate (Gibco; Thermo Fisher Scientific, Inc.) and 1% penicillin/streptomycin (Gibco; Thermo Fisher Scientific, Inc.) in 5% CO 2 at 37°C.

    Techniques: Expressing, Immunohistochemistry